BioWorld

Oct. 14, 2009

Heed All FDA Compliance Efforts, Drugmakers Warned by Panelists

Amarin's $70M: 'Mixing' It up Against Lovaza in Lipid Space

Corcept Raising $18M to Push Corlux Through Final Testing

Other News To Note

Clinic Roundup

Vanda Inks $465M Novartis Deal, but Acquisition Not off the Table

Five months after the surprise FDA approval of schizophrenia drug Fanapt (iloperidone), Vanda Pharmaceuticals Inc. nailed down a partner to launch the product. (BioWorld Today) Read More

Prosensa, GSK: $25M Up Front, Antisense to Make DMD Sense?

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 23, 2026

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration of red and white blood cells in an artery

Case report links APOLD1 variant to vascular-type bleeding disorder

BioWorld Science

Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.

2026 marks critical turning point for BCI technology

BioWorld

Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...